Structured evidence table for Citrus Bergamot Blood Glucose Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Citrus Bergamot Blood Glucose Randomized Trial | Data extraction focused on weight loss, body mass index, waist circumference, waist-to-hip ratio, and body fat percentage, and the risk of bias was assessed using the Revised Cochrane Risk-of-Bias Tool. | 1 | Pujia C (2026) | Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Citrus Bergamot Blood Glucose Randomized Trial | This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the effect of nutraceuticals containing Citrus bergamia on the management of obesity in adults by assessing measures related to obesity. | 1 | Pujia C (2026) | Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Citrus Bergamot Blood Glucose Randomized Trial | We searched the following databases until October 2024: PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials. | 1 | Pujia C (2026) | Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Citrus Bergamot Blood Glucose Randomized Trial | Epidemiological studies indicate that CRS affects a substantial proportion of patients, with an estimated prevalence of up to 0.4% in the general population and 2–3% in individuals with diabetes and heart failure, and is associated with increased morbidity and mortality [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Citrus Bergamot Blood Glucose Randomized Trial | Most preclinical studies investigating polyphenolic interventions have focused on type IV and type V CRS, particularly diabetes-induced chronic kidney disease with associated cardiovascular dysfunction [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Citrus Bergamot Blood Glucose Randomized Trial | Specifically, gut dysbiosis leads to an increased intestinal permeability (leaky gut), allowing the translocation of microbiota-derived uremic toxins (such as p-cresyl sulfate and TMAO) into the systemic circulation [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Citrus Bergamot Blood Glucose Randomized Trial | 1 2 3 4 5 6 7 1 2 1 2 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Figure 1 Cardiorenal syndromes (CRS) describe the complex bidirectional interaction between the heart and the kidneys, whereby acute or chronic dysfunction of one organ induces structural and functional impairment of the other []. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
Source documents